8th Annual Admet Conference is to Take Place in London, Uk, 10th – 11th July 2013
London (PRWEB UK) 13 June 2013
In less than 3 weeks, the highly anticipated Europe's leading ADMET conference will return to London with a two day content packed agenda featuring over 12 leading Pharma speakers within the field of ADMET. The event will provide the perfect platform to hear innovative presentation on themes including Predictive ADME, Screening Approaches, Pre-clinical Screening Approaches, and Predictive Toxicology, emerging issues such as regulatory changes and Drug-Drug interactions.
According to Alan Boobis, Professor of Biochemical Pharmacology, Imperial College London chairman on day one “Toxicology is undergoing a profound change. The dramatic advances in biology, technology, computing and mathematical analysis are being used to develop novel strategies for toxicity assessment. However, we are currently in a phase of transition, and it is not yet clear which approaches will advance drug development and which will hinder it.”
18 speakers from industry’s leading Pharma organisations will deliver case-studies and examine how new strategies in ADME impact drug discovery, development, safety and most importantly the subsequent clinical implications. Attendees will hear the latest on predictive toxicology, genotoxicity and metabolic toxicity, which will be addressed by organisations include: GlaxoSmithKline, Novo Nordisk, Sanofi-Aventis, Imperial College London and more.
A half day workshop on the 9th July will focus on Predictive Toxicology: Advantages and Limitations of In vitro and Computational methods will be lead by Mark Graham, Independent Drug Safety/Toxicology Consultant, MG Consulting (Former AstraZeneca Global Head).
Presentation highlights include:
· Alan Boobis, Professor of Biochemical Pharmacology, Imperial College London
TOXICITY PREDICTION IN DRUG DEVELOPMENT: OPPORTUNITIES AND CHALLENGES
· Stephen Clarke, Head Drug Metabolism & Pharmacokinetics, GlaxoSmithKline
HUMAN FIRST METABOLISM
· Jørgen Olsen, Principle Scientist, Novo Nordisk
PEPTIDES, PROTEINS, AND ADME
· Katharina Mertsch, Head of In-Vitro DMPK, Sanofi-aventis
IN VITRO PK PARAMETERS IN DISCOVERY AND DEVELOPMENT: BRIDGING HIGH THROUGHPUT, MODELLING, AND QUALITY FOR FDA/EMA REQUIREMENTS
Stephan Kirchner, Lab Head, In vitro Screening, F. Hoffmann-La Roche
EARLY GENOTOXICITY ASSESSMENT – AVOIDING LATE STAGE GENETOX FAILURES
Comments on last year’s ADMET programme include Instem Scientific – “Good balance of technical and scientific talks” and Sanofi-Aventis – “Great conference, well organised and high value topics”
Dale Butler, MD of event organiser SMi reported: "response to this year's event has been extremely positive thanks to the strength of industry bodies and technology specialists we have on board. We look forward to once again providing a Europe-wide platform for debate and knowledge-sharing amongst our varied communities, both in the lead up to and at the event itself."
For the full conference programme and further information please visit:
http://www.smi-online.co.uk/goto/2013admet43.asp
Alternatively contact Fateja Begum: +44(0) 20 7827 6184 / Email fbegum(at)smi-online(dot)co(dot)uk
Sponsorship opportunities are available for this event, please contact Alia Malick on +44(0) 20 7827 6168.
About SMi Group
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries.
We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. Reported by PRWeb 1 day ago.
London (PRWEB UK) 13 June 2013
In less than 3 weeks, the highly anticipated Europe's leading ADMET conference will return to London with a two day content packed agenda featuring over 12 leading Pharma speakers within the field of ADMET. The event will provide the perfect platform to hear innovative presentation on themes including Predictive ADME, Screening Approaches, Pre-clinical Screening Approaches, and Predictive Toxicology, emerging issues such as regulatory changes and Drug-Drug interactions.
According to Alan Boobis, Professor of Biochemical Pharmacology, Imperial College London chairman on day one “Toxicology is undergoing a profound change. The dramatic advances in biology, technology, computing and mathematical analysis are being used to develop novel strategies for toxicity assessment. However, we are currently in a phase of transition, and it is not yet clear which approaches will advance drug development and which will hinder it.”
18 speakers from industry’s leading Pharma organisations will deliver case-studies and examine how new strategies in ADME impact drug discovery, development, safety and most importantly the subsequent clinical implications. Attendees will hear the latest on predictive toxicology, genotoxicity and metabolic toxicity, which will be addressed by organisations include: GlaxoSmithKline, Novo Nordisk, Sanofi-Aventis, Imperial College London and more.
A half day workshop on the 9th July will focus on Predictive Toxicology: Advantages and Limitations of In vitro and Computational methods will be lead by Mark Graham, Independent Drug Safety/Toxicology Consultant, MG Consulting (Former AstraZeneca Global Head).
Presentation highlights include:
· Alan Boobis, Professor of Biochemical Pharmacology, Imperial College London
TOXICITY PREDICTION IN DRUG DEVELOPMENT: OPPORTUNITIES AND CHALLENGES
· Stephen Clarke, Head Drug Metabolism & Pharmacokinetics, GlaxoSmithKline
HUMAN FIRST METABOLISM
· Jørgen Olsen, Principle Scientist, Novo Nordisk
PEPTIDES, PROTEINS, AND ADME
· Katharina Mertsch, Head of In-Vitro DMPK, Sanofi-aventis
IN VITRO PK PARAMETERS IN DISCOVERY AND DEVELOPMENT: BRIDGING HIGH THROUGHPUT, MODELLING, AND QUALITY FOR FDA/EMA REQUIREMENTS
Stephan Kirchner, Lab Head, In vitro Screening, F. Hoffmann-La Roche
EARLY GENOTOXICITY ASSESSMENT – AVOIDING LATE STAGE GENETOX FAILURES
Comments on last year’s ADMET programme include Instem Scientific – “Good balance of technical and scientific talks” and Sanofi-Aventis – “Great conference, well organised and high value topics”
Dale Butler, MD of event organiser SMi reported: "response to this year's event has been extremely positive thanks to the strength of industry bodies and technology specialists we have on board. We look forward to once again providing a Europe-wide platform for debate and knowledge-sharing amongst our varied communities, both in the lead up to and at the event itself."
For the full conference programme and further information please visit:
http://www.smi-online.co.uk/goto/2013admet43.asp
Alternatively contact Fateja Begum: +44(0) 20 7827 6184 / Email fbegum(at)smi-online(dot)co(dot)uk
Sponsorship opportunities are available for this event, please contact Alia Malick on +44(0) 20 7827 6168.
About SMi Group
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries.
We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. Reported by PRWeb 1 day ago.